Eli Lilly Announces Groundbreaking Affordable Insulin Program.
Lately, we are inundated with negative reports and information surrounding the Coronavirus outbreak. Fortunately, there is some good news for people with type 1 diabetes. Eli Lilly announced that beginning April 6, 2020, and for $35.00 dollars a month regardless of having a health insurance plan or not having health insurance at all, people with …
Continue reading “Eli Lilly Announces Groundbreaking Affordable Insulin Program.”
How People With Diabetes and Others Can Get Early Supplies of Essential Medicine
As the novel coronavirus COVID-19 continues to spread in the United States, many people are understandably concerned about access to their medications. Health officials and medical professionals working in federal, state and local governments recommend that high-risk individuals with underlying health conditions such as Type 1 Diabetes, stock up on their prescription medications, in addition to practicing basic hygiene and avoiding crowded places.
Diasome Announces Positive Results for HDV Insulin Additive to Manage Blood Sugar
Diasome Pharmaceuticals announced positive results this week from a Phase 2 study of its injectable hepatocyte directed vesicle (HDV) additive for insulin in patients with type 1 diabetes. The news could prove a major step forward for therapies that aim to improve and optimize the way insulin is used and metabolized by the body. In …
Continue reading “Diasome Announces Positive Results for HDV Insulin Additive to Manage Blood Sugar”
Pharma and Medtech CEOs at JPMorgan 2020 Weigh in on Insulin Pricing, Supply Issues, and Innovation
Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.
FDA Approves Fiasp Ultra-Fast Acting Insulin for Children with Type 1 Diabetes
The U.S. Food and Drug Administration has approved Novo Nordisk’s fast-acting Fiasp insulin for use in children as well as adults, the pharmaceutical firm announced Monday.
